Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Ascletis Pharma Inc

Healthcare US ASCLF

1.35USD
0.00(0%)

Last update at 2026-06-22T20:00:00Z

Day Range

1.351.35
LowHigh

52 Week Range

0.812.29
LowHigh

Fundamentals

  • Previous Close 1.35
  • Market Cap2424.63M
  • Volume1000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-471.64701M
  • Revenue TTM2.03M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.53M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -350.10005M -300.93600M -144.71500M -314.84300M -199.01700M
Minority interest - - - - -
Net income -350.59298M -300.93600M -144.71500M -314.84300M -199.01700M
Selling general administrative - 101.74M 62.58M 15.43M 16.49M
Selling and marketing expenses - - 0.39M 16.98M 20.87M
Gross profit -16.64898M 0.73M 25.99M -24.69200M 39.17M
Reconciled depreciation - 20.45M 18.48M 30.19M 29.55M
Ebit -471.27421M -404.63300M -144.57100M -262.81700M -195.89600M
Ebitda -454.11184M -390.45000M -126.09100M -232.62600M -166.35100M
Depreciation and amortization 17.16M 14.18M 18.48M 30.19M 29.55M
Non operating income net other - - - - -
Operating income -471.27421M -295.41900M -300.20800M -262.81700M -195.89600M
Other operating expenses 473.25M 296.70M 356.80M 393.72M 260.96M
Interest expense 0.16M 0.24M 0.14M 0.16M 0.12M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 92.24M 99.28M 44.16M 22.51M
Net interest income - 91.99M 99.13M 44.01M 22.38M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.49294M - 95.40M - -
Total revenue 1.98M 1.28M 56.60M 54.09M 76.88M
Total operating expenses 454.63M 296.15M 326.20M 314.94M 223.26M
Cost of revenue 18.62M 0.55M 30.61M 78.78M 37.70M
Total other income expense net 121.17M -5.51700M 155.49M -52.02600M -3.12100M
Discontinued operations - - - - -
Net income from continuing ops - -300.93600M -144.71500M -314.84300M -199.01700M
Net income applicable to common shares - - - -314.84300M -199.01700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2067.57M 2124.57M 2491.01M 2657.04M 2829.96M
Intangible assets - 12.12M 26.32M 16.56M 78.21M
Earning assets - - - - -
Other current assets 4.75M 13.74M 19.43M 8.12M 2.34M
Total liab 129.94M 158.41M 148.94M 117.16M 100.89M
Total stockholder equity 1935.24M 1966.16M 2342.07M 2539.89M 2729.07M
Deferred long term liab - - - 0.70M 0.42M
Other current liab 123.44M 142.70M 132.60M 102.64M 88.35M
Common stock 0.68M 0.69M 0.73M 0.74M 0.75M
Capital stock - 0.69M 0.73M 0.74M 0.75M
Retained earnings - -1475.33900M -1174.40300M -1029.68800M -714.84500M
Other liab - - - 7.15M 8.73M
Good will - - - - -
Other assets - - - 1.91M 0.83M
Cash 1444.24M 865.73M 330.12M 2470.83M 2495.50M
Cash and equivalents - - - - -
Total current liabilities 127.66M 153.05M 140.68M 108.19M 90.97M
Current deferred revenue - - -5.71000M - -
Net debt -1439.08154M -858.09700M -321.70100M -2466.59700M -2492.74600M
Short term debt 2.87M 6.25M 5.71M 2.42M 1.57M
Short long term debt - - - - -
Short long term debt total 5.16M 7.63M 8.42M 4.24M 2.75M
Other stockholder equity 1934.56M 2693.26M 2791.18M 3568.83M 2728.33M
Property plant equipment - - - 71.83M 77.51M
Total current assets 1921.69M 1970.78M 2332.76M 2544.73M 2631.55M
Long term investments - - - - -
Net tangible assets - - - 2523.33M 2650.86M
Short term investments 457.59M 1081.80M 1969.29M 11.20M 5.20M
Net receivables 13.23M 5.14M 4.00M 23.87M 67.39M
Long term debt - - - - -
Inventory 1.87M 4.37M 6.07M 20.52M 56.23M
Accounts payable 1.34M 0.03M 0.65M 3.13M 1.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 747.55M 724.56M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.46M 1081.88M 1969.92M 11.90M 5.62M
Deferred long term asset charges - - - - -
Non current assets total 145.88M 153.79M 158.25M 112.32M 198.41M
Capital lease obligations - 7.63M 8.42M 4.24M 2.75M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 978.91M 149.84M -1297.38700M -269.77800M 170.96M
Change to liabilities - - 0.49M -2.48500M -7.43700M
Total cashflows from investing activities 978.91M 149.84M -1297.38700M -274.49200M 132.30M
Net borrowings - - -2.22300M -2.28400M -1.93400M
Total cash from financing activities -103.50800M -81.49600M -1.41900M -31.09800M -21.67000M
Change to operating activities - - 16.41M 24.37M -6.66900M
Net income -300.93600M -144.71500M -314.84300M -199.01700M -209.24100M
Change in cash 534.21M -73.65100M -1323.64300M -483.09300M -84.54000M
Begin period cash flow 330.12M 403.77M 1727.41M 2210.50M 2295.04M
End period cash flow 864.33M 330.12M 403.77M 1727.41M 2210.50M
Total cash from operating activities -341.57900M -144.16200M -142.45300M -146.93000M -84.91100M
Issuance of capital stock - 0.00000M 0.96M - -
Depreciation 20.45M 18.48M 30.19M 29.55M 27.16M
Other cashflows from investing activities 121.09M -12.82100M 3.32M 2.48M 0.29M
Dividends paid - - - - -
Change to inventory -3.59800M -8.05400M -12.83900M -5.06800M -18.37300M
Change to account receivables 5.28M 18.44M 29.74M -26.99300M 42.98M
Sale purchase of stock -98.53100M -78.96100M 0.00000M -28.68900M -19.60100M
Other cashflows from financing activities -0.24400M -0.14400M -2.38000M -2.40900M -2.06900M
Change to netincome - - 108.08M 32.29M 86.22M
Capital expenditures 2.15M 19.16M 14.40M 7.20M 38.96M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 13.79M 38.53M 33.81M -10.17500M 10.43M
Stock based compensation 3.00M 1.33M 3.19M 7.13M 4.61M
Other non cash items -77.88700M -57.78400M 105.20M 25.59M 82.13M
Free cash flow -343.72700M -163.32000M -156.85400M -154.12800M -123.87100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASCLF
Ascletis Pharma Inc		 - -% 1.35 - - 1195.58 7.81 7500.86 -0.1345
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.

Ascletis Pharma Inc

12/F, Building D, Hangzhou, China, 311200

Key Executives

Name Title Year Born
Dr. Jinzi Jason Wu Founder, Chairman & CEO 1963
Dr. Handan He Ph.D. Chief Scientific Officer 1962
Ms. Hejingdao Wu Sr. VP of Operations & Exec. Director 1974
Ms. Yuemei Yan Sr. VP of Clinical Devel. Operations 1970
Dr. Kristjan Sigurdur Gudmundsson Sr. Consultant & Head of Discovery 1968
Dr. George Zhengzhi Hill Sr. Consultant & Chief Medical Advisor 1951
Mr. John P. Gargiulo M.B.A. Chief Bus. Officer NA
Mr. Ming Fai Chung CPA Company Sec. NA
Dr. Jinzi Jason Wu Ph.D. Founder, Chairman & CEO 1964
Ms. Hejingdao Wu Senior VP of Operations & Executive Director 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions